| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/09273941003721926 |
| P698 | PubMed publication ID | 20482396 |
| P50 | author | Yolanda Diebold | Q43119616 |
| Margarita Calonge | Q43119624 | ||
| Roberto Reinoso | Q46698086 | ||
| María Jesús González-García | Q55704459 | ||
| Alfredo Corell | Q64356118 | ||
| P2093 | author name string | José M Herreras | |
| Amalia Enríquez-de-Salamanca | |||
| P2860 | cites work | Prevalence of dry eye syndrome among US women | Q28196875 |
| Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome | Q28587895 | ||
| Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. | Q30813799 | ||
| Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline | Q30818365 | ||
| Apoptosis of ocular surface cells in experimentally induced dry eye. | Q33185569 | ||
| Protective Effect ofd-β-Hydroxybutyrate on Corneal Epithelia in Dry Eye Conditions through Suppression of Apoptosis | Q33194215 | ||
| Desiccating stress decreases apical corneal epithelial cell size--modulation by the metalloproteinase inhibitor doxycycline | Q33362899 | ||
| Androgens and dry eye in Sjögren's syndrome | Q33692681 | ||
| Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies | Q33720070 | ||
| Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model | Q33793715 | ||
| Epithelial-immune cell interaction in dry eye. | Q33850150 | ||
| Histology of the lacrimal gland in keratoconjunctivitis sicca | Q33997341 | ||
| Characterization of effector T cells in dry eye disease | Q34065949 | ||
| The pathology of dry eye. | Q34391929 | ||
| Diagnosis of dry eye. | Q34391935 | ||
| The treatment of dry eye. | Q34391944 | ||
| The epidemiology of dry eye in Melbourne, Australia | Q34471837 | ||
| Historical insights into cytokines | Q34708047 | ||
| Topical omega-3 and omega-6 fatty acids for treatment of dry eye. | Q34749224 | ||
| Regulation of mucin and fluid secretion by conjunctival epithelial cells | Q34998317 | ||
| The role of the lacrimal functional unit in the pathophysiology of dry eye. | Q35755146 | ||
| Animal models of dry eye: a critical assessment of opportunities and limitations | Q35783141 | ||
| The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren's syndrome (autoimmune epithelitis). | Q36500399 | ||
| Tear cytokine profiles in dysfunctional tear syndrome. | Q36637791 | ||
| Dysfunctional tear syndrome: a Delphi approach to treatment recommendations | Q36653052 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome | Q36676823 | ||
| Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice | Q36744949 | ||
| Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression | Q37071969 | ||
| Animal models of dry eye. | Q37153474 | ||
| Dry eyes: etiology and management | Q37188359 | ||
| Advances in understanding and managing dry eye disease | Q37206550 | ||
| Evaluation of novel dry eye model: preganglionic parasympathetic denervation in rabbit | Q37258314 | ||
| Rationale for anti-inflammatory therapy in dry eye syndrome | Q37410903 | ||
| sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised | Q37726033 | ||
| Cytokines and chemokines in immune-based ocular surface inflammation. | Q37755206 | ||
| Tear physiology and dry eyes | Q39709731 | ||
| Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation | Q39945050 | ||
| Meibomian gland dysfunction | Q41089196 | ||
| Important concepts for treating ocular surface and tear disorders | Q41664259 | ||
| The immunomodulatory role of human conjunctival epithelial cells | Q42446603 | ||
| Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye. | Q44559318 | ||
| Conjunctival Cytologiec Features of Primary Sjögren's Syndrome | Q44908495 | ||
| A novel porcine dry eye model system (pDEM) with simulated lacrimation/blinking system: preliminary findings on system variability and effect of corneal drying | Q45002210 | ||
| Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface | Q45158772 | ||
| Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca | Q45190856 | ||
| Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. | Q45930063 | ||
| Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease | Q46209348 | ||
| Topical apolipoprotein A-1 may have a beneficial effect on the corneal epithelium in a mouse model of dry eye: a pilot study | Q46380434 | ||
| In vitro expanded CD4+CD25+Foxp3+ regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation | Q46460388 | ||
| Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye. | Q46466345 | ||
| D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board | Q46568367 | ||
| The controlled-environment chamber: a new mouse model of dry eye. | Q46618772 | ||
| The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy | Q46658333 | ||
| A murine model of dry eye induced by an intelligently controlled environmental system | Q46667392 | ||
| Time course of ocular surface and lacrimal gland changes in a new scopolamine-induced dry eye model | Q46689617 | ||
| Dry eye and blink rate simulation with a pig eye model | Q46736124 | ||
| Exposure to a controlled adverse environment impairs the ocular surface of subjects with minimally symptomatic dry eye. | Q50681036 | ||
| Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. | Q50721017 | ||
| Meibomian gland dysfunction in patients with Sjögren syndrome. | Q50870035 | ||
| Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. | Q51546545 | ||
| Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. | Q53572321 | ||
| Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. | Q54602794 | ||
| CCR4 and CCR5 expression in conjunctival specimens as differential markers of TH1/ TH2 in ocular surface disorders | Q57693376 | ||
| Conjunctival Epithelium Expression of HLA-DR in Dry Eye Patients | Q58205031 | ||
| P433 | issue | 4 | |
| P921 | main subject | eye disease | Q3041498 |
| inflammation | Q101991 | ||
| P304 | page(s) | 244-253 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Ocular Immunology and Inflammation | Q15760486 |
| P1476 | title | Dry eye disease as an inflammatory disorder | |
| P478 | volume | 18 |
| Q35909290 | Activation of Dll4/Notch Signaling and Hypoxia-Inducible Factor-1 Alpha Facilitates Lymphangiogenesis in Lacrimal Glands in Dry Eye |
| Q36179830 | Alcohol consumption and dry eye syndrome: a Meta-analysis |
| Q46893944 | Antioxidant effect of 0.2% xanthan gum in ocular surface corneal epithelial cells |
| Q38733230 | Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting |
| Q52643805 | Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease. |
| Q36656777 | Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping |
| Q35422889 | Correlations between eyelid tumors and tear lipocalin, lysozyme and lactoferrin concentrations in postmenopausal women |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q38810021 | Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease. |
| Q91945885 | Diagnosing the Dry Eye Syndrome in modern society and among patients with glaucoma: a prospective study |
| Q34092386 | Diagnosing the severity of dry eye: a clear and practical algorithm |
| Q39730888 | Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. |
| Q36799601 | Dry eye disease and microbial keratitis: is there a connection? |
| Q43929308 | Dry eye disease in French elderly subjects: the Alienor Study |
| Q41560816 | Effect of hyaluronic acid on tear film thickness as assessed with ultra-high resolution optical coherence tomography |
| Q40277929 | Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model |
| Q37692232 | Effects of silk fibroin in murine dry eye. |
| Q35754989 | Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye |
| Q35201781 | Electrophoresis of tear proteins as a new diagnostic tool for two high risk groups for dry eye: computer users and contact lens wearers. |
| Q37359850 | Evaluation of patients with dry eye disease for conjunctival Chlamydia trachomatis and Ureaplasma urealyticum |
| Q35177377 | Evidence for TRPA1 involvement in central neural mechanisms in a rat model of dry eye. |
| Q41685645 | Hepatitis C virus core and NS3 antigens induced conjunctival inflammation via toll-like receptor-mediated signaling |
| Q55010929 | High-Mobility Group Box 1 in Dry Eye Inflammation. |
| Q36845553 | Hyaluronate Acid-Dependent Protection and Enhanced Corneal Wound Healing against Oxidative Damage in Corneal Epithelial Cells |
| Q95840976 | Intravital Multiphoton Microscopy of the Ocular Surface: Alterations in Conventional Dendritic Cell Morphology and Kinetics in Dry Eye Disease |
| Q50002245 | Justifiability and Animal Research in Health: Can Democratisation Help Resolve Difficulties? |
| Q39365232 | Non-invasive objective and contemporary methods for measuring ocular surface inflammation in soft contact lens wearers - A review. |
| Q38038206 | Ocular actions of platelet-activating factor: clinical implications |
| Q42506915 | Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. |
| Q52558847 | Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. |
| Q55618002 | RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. |
| Q33616767 | Restoration of Tear Secretion in a Murine Dry Eye Model by Oral Administration of Palmitoleic Acid |
| Q41990297 | Role of NFAT5 in inflammatory disorders associated with osmotic stress |
| Q35472653 | Sensitization of trigeminal brainstem pathways in a model for tear deficient dry eye |
| Q90481097 | TRPV1 and TRPM8 Channels and Nocifensive Behavior in a Rat Model for Dry Eye |
| Q36041432 | Tear lipocalin, lysozyme and lactoferrin concentrations in postmenopausal women |
| Q34510429 | The core mechanism of dry eye disease is inflammation |
| Q41484441 | The effect of intravitreal injections on dry eye, and proposed management strategies |
| Q45069146 | The effects of topical aqueous sirolimus on tear production in normal dogs and dogs with refractory dry eye. |
| Q39820355 | The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride-induced murine dry eye model |
| Q36384149 | Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies? |
Search more.